Meeting
2014 ASCO Annual Meeting
A phase II study with lead-in safety cohort of cabazitaxel (C) plus lapatinib (L) as therapy for HER2+ metastatic breast cancer (MBC) with intracranial metastases (mets).
Authors
Denise A. Yardley
Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN
Denise A. Yardley , John D. Hainsworth , Erika Paige Hamilton , Lowell L. Hart , Mythili Shastry , Laura M. DeBusk , Howard A. Burris III
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
NCT01934894
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS667)
DOI
10.1200/jco.2014.32.15_suppl.tps667
Abstract #
TPS667
Poster Bd #
123B
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
An open-label positron emission tomography (PET) study to investigate and quantify brain and tumor penetration of carbon-11 labeled lapatinib in patients with HER2-overexpressing (HER2+) advanced or metastatic breast cancer (MBC).
First Author: R. C. Coombes
First Author: Nicholas Patrick McAndrew
Poster
2021 ASCO Annual Meeting
Pyrotinib plus capecitabine for HER2-positive metastatic breast cancer patients with brain metastases (PERMEATE): A multicenter, single-arm phase II study.
First Author: Min Yan
Poster
2015 ASCO Annual Meeting
Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib + paclitaxel vs trastuzumab + paclitaxel as first-line treatment for HER2+ metastatic breast cancer (NEfERTT).
First Author: Ahmad Awada